Loading stock data…
NVO
$43.88+1.66 (+3.93%)
Pre-Market$43.87-0.01 (-0.02%)· Last close May 1
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Novo Nordisk A/S in the Healthcare sector is trading at $43.88. The stock is currently near its 52-week low of $35.12, remaining 9.3% below its 200-day moving average. Technical signals show overbought RSI of 74 and bullish MACD crossover, explaining why NVO maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Overbought levels (RSI 74) — risk of consolidation or pullback
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$43.88
Potential Upside
173%
Whystock Fair Value$119.81
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus12 analysts
Buy
Mean target$46.67+6.4%
Range$36.08 – $65.88
Fundamentals
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabet...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$175.96B
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
10.79
Beta
Defensive asset. Lower volatility than the S&P 500.
0.27
Div Yield
Strong income play. Yield provides a meaningful total return floor.
457.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
57.24%
Volume
Today's trading volume
25.46M
Recent News
Novo Nordisk Extends Pipeline With Semaglutide Alcohol Study And LX9851 Trial
Novo Nordisk (NYSE:NVO) is exploring semaglutide as a potential treatment for alcohol use disorder, expanding beyond its current uses in diabetes and obesity. The company has also begun Phase 1 trials for LX9851, an oral obesity and metabolic disorder drug developed with Lexicon Pharmaceuticals. These moves highlight ongoing clinical work in metabolic and related conditions, with implications for future treatment options. Novo Nordisk is currently trading at $43.88, with the share price up...
Is Novo Nordisk A/S (NVO) A Good Stock To Buy Now?
Is NVO a good stock to buy? We came across a bullish thesis on Novo Nordisk A/S on Unfair Advantage’s Substack by AK. In this article, we will summarize the bulls’ thesis on NVO. Novo Nordisk A/S’s share was trading at $38.52 as of April 23rd. NVO’s trailing and forward P/E were 10.65 and 11.38 respectively according […]
Jobs Report, Palantir, Pinterest, AMD, PayPal, Disney, and More to Watch This Week
ON Semiconductor, Pfizer, Uber, McDonald’s, and many more will report earnings this week. Economic releases will include the April jobs report and purchasing managers index.
Why GoodRx (GDRX) Stock Is Trading Up Today
Shares of healthcare tech company GoodRx (NASDAQ:GDRX) jumped 9.5% in the afternoon session after it announced it would provide access to Novo Nordisk's oral semaglutide medication, known as the Ozempic pill, for eligible self-pay patients with type 2 diabetes.
Jim Cramer Praises Eli Lilly’s Performance
Eli Lilly and Company (NYSE:LLY) was among the stocks Jim Cramer highlighted, as he discussed the massive AI infrastructure buildout. Cramer noted that the company is “creating a lot of jobs,” as he said: Okay, then there’s one that’s totally away from manufacturing or industry or tech, and that’s Eli Lilly. It was up 10%. […]